Halozyme Q3 revenue up 22%, raises 2025 guidance, CFO transition announced

HALOZYME THERAPEUTICS, INC.

2025-Q3 EPS reported $3.68 vs consensus $1.66 ▲ beat (+121.6%)

Q3 2025 revenue $354M (+22% YoY); royalty revenue $236M (+52% YoY); GAAP diluted EPS $1.43 (+36% YoY); non-GAAP diluted EPS $1.72 (+35% YoY).
Raises full-year 2025 guidance: total revenue $1,300-$1,375M, royalty $850-$880M, Adj. EBITDA $885-$935M, non-GAAP EPS $6.10-$6.50.
Agreed to acquire Elektrofi for $750M up-front plus up to $150M in milestones; expected close Q4 2025.
CFO Nicole LaBrosse to depart by March 30, 2026 or when successor hired; external search underway; departure not due to disagreement.
Two new indication approvals: DARZALEX SC for smoldering multiple myeloma in Europe; VYVDURA prefilled syringe in Japan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.